During the years, Dr. Naftali conducted research in the field of functional bowel diseases, including esophageal motility problems, gastroparesis, chronic constipation, fecal incontinence and more. In the field of IBD Dr. Naftali published studies involving, among other topics, treatment with cyclosporine in sever ulcerative colitis, adherence of patients to medical treatment, and more.
Furthermore, Dr. Naftali published several pioneering studies regarding cannabis treatment in sever IBD. These studies have shown that although cannabis does not improve the inflammation, it can induce symptomatic relief. In order to further understand the effect of cannabis on IBD Dr. Naftali established the Gastro Cannabis laboratory in which the exploration of the effect of cannabinoids on the gastrointestinal tract continues.
Dr. Timna Naftali Graduated from the Sackler school of medicine in Tel Aviv university. She has been a specialist in internal medicine since 1992 and in Gastroenterology since 1998, after an internship in Meir hospital in Kefar Saba, Israel. Between the years 1998-2016 Dr. Naftali worked in the Gastroenterology community clinic in Herzliya, in combination with her role as a senior physician in the institute of Gastroenterology in Meir hospital. Dr. Naftali also trained in functional bowl diseases in St. Marks hospital in London, England and in Mayo Clinic in Minnesota, US. As of 2016 Dr. Naftali is the deputy director of the institute of Gastroenterology in Meir hospital and is running the service for inflammatory bowel disease.
Dr. Naftali is an active participant in many international conferences. She is a senior lecturer in the Sackler school of medicine and a member of the Israeli Gastroenterology association, the IBD group and the neurogastroenterology group. In addition, Dr. Naftali established and is running the inflammatory bowel disease (IBD) service in Meir hospital, with an emphasis on conducting a multidisciplinary team including gastroenterologists, surgeons, dietitians, psychologists and nurses in order to answer the many needs of IBD patients.